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reamble
t is important that the medical profession play a significant
ole in critically evaluating the use of diagnostic procedures
nd therapies as they are introduced and tested in the
etection, management, or prevention of disease states.
igorous and expert analysis of the available data docu-
enting absolute and relative benefits and risks of those
rocedures and therapies can produce helpful guidelines
hat improve the effectiveness of care, optimize patient
utcomes, and favorably affect the overall cost of care by
ocusing resources on the most effective strategies.
The American College of Cardiology Foundation
ACCF) and the American Heart Association (AHA) have
ointly engaged in the production of such guidelines in the
rea of cardiovascular disease since 1980. The American
ollege of Cardiology (ACC)/AHA Task Force on Practice
uidelines, whose charge is to develop, update, or revise
ractice guidelines for important cardiovascular diseases and
rocedures, directs this effort. Writing committees are
harged with the task of performing an assessment of the
vidence and acting as an independent group of authors to
evelop, update, or revise written recommendations for
linical practice.
Experts in the subject under consideration have been
elected from both organizations to examine subject-specific
ata and write guidelines. The process includes additional
epresentatives from other medical practitioner and specialty
roups when appropriate. Writing committees are specifi-
ally charged to perform a formal literature review, weigh
he strength of evidence for or against a particular treatment
r procedure, and include estimates of expected health
utcomes where data exist. Patient-specific modifiers and
omorbidities and issues of patient preference that may
nfluence the choice of particular tests or therapies are
onsidered, as well as frequency of follow-up and cost-
ffectiveness. When available, information from studies on
ost will be considered; however, review of data on efficacy
nd clinical outcomes will constitute the primary basis for
reparing recommendations in these guidelines.
The ACC/AHA Task Force on Practice Guidelines
akes every effort to avoid any actual, potential, or per-
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May 27, 2008:2085–105 ACC/AHA/HRS Guidelines for Device-Based Therapy: Executive Summaryeived conflicts of interest that may arise as a result of an
ndustry relationship or personal interest of the writing
ommittee. Specifically, all members of the writing com-
ittee, as well as peer reviewers of the document, were
sked to provide disclosure statements of all such relation-
hips that may be perceived as real or potential conflicts of
nterest. Writing committee members are also strongly
ncouraged to declare a previous relationship with industry
hat may be perceived as relevant to guideline development.
f a writing committee member develops a new relationship
ith industry during his or her tenure, he or she is required
o notify guideline staff in writing. The continued partici-
ation of the writing committee member will be reviewed.
hese statements are reviewed by the parent task force,
eported orally to all members of the writing committee at
ach meeting, and updated and reviewed by the writing
ommittee as changes occur. Please refer to the methodol-
gy manual for ACC/AHA guideline writing committees
or further description of the relationships with industry
olicy (1). See Appendix 1 for author relationships with
ndustry and Appendix 2 for peer reviewer relationships
ith industry that are pertinent to this guideline.
These practice guidelines are intended to assist health
are providers in clinical decision making by describing a
ange of generally acceptable approaches for the diagnosis,
anagement, and prevention of specific diseases or condi-
ions. Clinical decision making should consider the quality
nd availability of expertise in the area where care is
rovided. These guidelines attempt to define practices that
eet the needs of most patients in most circumstances.
hese guideline recommendations reflect a consensus of
xpert opinion after a thorough review of the available
urrent scientific evidence and are intended to improve
atient care.
Patient adherence to prescribed and agreed upon medical
egimens and lifestyles is an important aspect of treatment.
rescribed courses of treatment in accordance with these
ecommendations will only be effective if they are followed.
ecause lack of patient understanding and adherence may
dversely affect treatment outcomes, physicians and other
ealth care providers should make every effort to engage the
atient in active participation with prescribed medical reg-
mens and lifestyles.
If these guidelines are used as the basis for regulatory or
ayer decisions, the ultimate goal is quality of care and serving
he patient’s best interests. The ultimate judgment regarding
are of a particular patient must be made by the health care
rovider and the patient in light of all of the circumstances
resented by that patient. There are circumstances in which
eviations from these guidelines are appropriate.
The guidelines will be reviewed annually by the ACC/
HA Task Force on Practice Guidelines and will be
onsidered current unless they are updated, revised, or
unsetted and withdrawn from distribution. The executive
ummary and recommendations are published in the May
7, 2008, issue of the Journal of the American College of Tardiology, May 27, 2008, issue of Circulation, and the June
008 issue of Heart Rhythm. The full-text guidelines are
-published in the same issue of the journals noted above, as
ell as posted on the ACC (www.acc.org), AHA (http://
y.americanheart.org), and Heart Rhythm Society (HRS)
www.hrsonline.org) Web sites. Copies of the full-text and
he executive summary are available from each organization.
Sidney C. Smith, Jr, MD, FACC, FAHA
Chair, ACC/AHA Task Force on Practice Guidelines
. Introduction
.1. Organization of Committee
his revision of the “ACC/AHA/NASPE Guidelines for
mplantation of Cardiac Pacemakers and Antiarrhythmia
evices” updates the previous versions published in 1984,
991, 1998, and 2002. Revision of the statement was
eemed necessary for multiple reasons: 1) Major studies
ave been reported that have advanced our knowledge of the
atural history of bradyarrhythmias and tachyarrhythmias,
hich may be treated optimally with device therapy; 2)
here have been tremendous changes in the management of
eart failure that involve both drug and device therapy; and
) major advances in the technology of devices to treat,
elay, and even prevent morbidity and mortality from
radyarrhythmias, tachyarrhythmias, and heart failure have
ccurred.
The committee to revise the “ACC/AHA/NASPE
uidelines for Implantation of Cardiac Pacemakers and
ntiarrhythmia Devices” was composed of physicians who
re experts in the areas of device therapy and follow-up and
enior clinicians skilled in cardiovascular care, internal
edicine, cardiovascular surgery, ethics, and socioeconom-
cs. The committee included representatives of the Ameri-
an Association for Thoracic Surgery, Heart Failure Society
f America, and Society of Thoracic Surgeons.
.2. Document Review and Approval
he document was reviewed by 2 official reviewers nomi-
ated by each of the ACC, AHA, and HRS and by 11
dditional peer reviewers. Of the total 17 peer reviewers, 10
ad no significant relevant relationships with industry. In
ddition, this document has been reviewed and approved by
he governing bodies of the ACC, AHA, and HRS, which
nclude 19 ACC Board of Trustees members (none of
hom had any significant relevant relationships with indus-
ry), 15 AHA Science Advisory Coordinating Committee
embers (none of whom had any significant relevant
elationships with industry), and 14 HRS Board of Trustees
embers (6 of whom had no significant relevant relation-
hips with industry). All guideline recommendations under-
ent a formal, blinded writing committee vote. Writing
ommittee members were required to recuse themselves if
hey had a significant relevant relationship with industry.
he guideline recommendations were unanimously ap-
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ligible to vote.
.3. Methodology and Evidence
he recommendations listed in this document are, when-
ver possible, evidence based. An extensive literature survey
as conducted and limited to studies, reviews, and other
vidence conducted in human subjects and published in
nglish. Additionally, the committee reviewed documents
elated to the subject matter previously published by the
CC, AHA, and HRS. References selected and published
n this document are representative and not all-inclusive.
The committee reviewed and ranked evidence supporting
urrent recommendations, with the weight of evidence
anked as Level A if the data were derived from multiple
andomized clinical trials that involved a large number of
ndividuals. The committee ranked available evidence as
evel B when data were derived either from a limited
umber of trials that involved a comparatively small number
f patients or from well-designed data analyses of nonran-
omized studies or observational data registries. Evidence
as ranked as Level C when the consensus of experts was
he primary source of the recommendation. In the narrative
ortions of these guidelines, evidence is generally presented
n chronological order of development. Studies are identi-
ed as observational, randomized, prospective, or retrospec-
ive. The committee emphasizes that for certain conditions
or which no other therapy is available, the indications for
evice therapy are based on expert consensus and years of
linical experience and are thus well supported, even though
he evidence was ranked as Level C. An analogous example
s the use of penicillin in pneumococcal pneumonia, for
hich there are no randomized trials and only clinical
xperience. When indications at Level C are supported by
istorical clinical data, appropriate references (e.g., case
eports and clinical reviews) are cited if available. When
evel C indications are based strictly on committee consen-
us, no references are cited. In areas where sparse data were
vailable (e.g., pacing in children and adolescents), a survey
f current practices of major centers in North America was
onducted to determine whether there was a consensus
egarding specific pacing indications.
The schema for classification of recommendations and
evel of evidence is summarized in Table 1, which also
llustrates how the grading system provides an estimate of
he size of the treatment effect and an estimate of the
ertainty of the treatment effect.
The focus of these guidelines is the appropriate use of
evices (e.g., pacemakers for bradyarrhythmias and heart
ailure management, cardiac resynchronization, and im-
lantable cardioverter-defibrillators [ICDs]), not the treat-
ent of cardiac arrhythmias. The fact that the use of a
evice for treatment of a particular condition is listed as a
lass I indication (beneficial, useful, and effective) does not
reclude the use of other therapeutic modalities that may be
qually effective. As with all clinical practice guidelines, the lecommendations in this document focus on treatment of an
verage patient with a specific disorder and may be modified by
atient comorbidities, limitation of life expectancy because of
oexisting diseases, and other situations that only the primary
reating physician may evaluate appropriately.
The term “symptomatic bradycardia” is used in this
ocument. Symptomatic bradycardia is defined as a docu-
ented bradyarrhythmia that is directly responsible for
evelopment of the clinical manifestations of syncope or
ear syncope, transient dizziness or lightheadedness, or
onfusional states resulting from cerebral hypoperfusion
ttributable to slow heart rate. Fatigue, exercise intolerance,
nd congestive heart failure may also result from bradycar-
ia. These symptoms may occur at rest or with exertion.
efinite correlation of symptoms with a bradyarrhythmia is
equired to fulfill the criteria that define symptomatic
radycardia. Caution should be exercised not to confuse
hysiological sinus bradycardia (as occurs in highly trained
thletes) with pathological bradyarrhythmias. Occasionally,
ymptoms may become apparent only in retrospect after
ntibradycardia pacing. Nevertheless, the universal applica-
ion of pacing therapy to treat a specific heart rate cannot be
ecommended except in specific circumstances, as detailed
ubsequently.
In these guidelines, the terms “persistent,” “transient,”
nd “not expected to resolve” are used but not specifically
efined because the time element varies in different clinical
onditions. The treating physician must use appropriate
linical judgment and available data in deciding when a
ondition is persistent or when it can be expected to be
ransient.
Recommendations for ICD implantation have been up-
ated to reflect the numerous new developments in this field
nd the voluminous literature related to the efficacy of these
evices in the treatment and prophylaxis of sudden cardiac
eath (SCD) and malignant ventricular arrhythmias. Indi-
ations for ICDs, cardiac resynchronization therapy (CRT)
evices, and combined ICDs and CRT devices are contin-
ously changing and can be expected to change further as
ew trials are reported. Indeed, it is inevitable that the
ndications for device therapy will be refined with respect to
oth expanded use and the identification of patients ex-
ected to benefit the most from these therapies. Further-
ore, it is emphasized that when a patient has an indication
or both a pacemaker (whether it be single-chamber, dual-
hamber, or biventricular) and an ICD, a combined device
ith appropriate programming is indicated.
The 2008 revision reflects what the committee believes
re the most relevant and significant advances in pacemaker/
CD therapy since the publication of these guidelines in the
ournal of the American College of Cardiology and Circulation
n 2002 (2,3).
All recommendations assume that patients are treated
ith optimal medical therapy according to published guide-ines, as had been required in all the randomized controlled
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ommittee believes that comorbidities, life expectancy, and
uality-of-life issues must be addressed forthrightly with
atients and their families. We have repeatedly used the
hrase “reasonable expectation of survival with a good
unctional status for more than 1 year” to emphasize this
ntegration of factors in decision making. Even when
hysicians believe that the anticipated benefits warrant
able 1. Applying Classification of Recommendations and Leveevice implantation, patients have the option to declinentervention after having been provided with a full explana-
ion of the potential risks and benefits of device therapy.
inally, the committee is aware that other guidelines/expert
roups have interpreted the same data differently (4–7).
In preparing this revision, the committee was guided by
he following principles:
. Changes in recommendations and levels of evidence
videncel of Ewere made either because of new randomized trials or
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the development of clinical consensus.
. The committee was cognizant of the health care, logistic,
and financial implications of recent trials and factored in
these considerations to arrive at the classification of
certain recommendations.
. For recommendations taken from other guidelines,
wording changes were made to render some of the
original recommendations more precise.
. The committee would like to re-emphasize that the
recommendations in this guideline apply to most pa-
tients but may require modification because of existing
situations that only the primary treating physician can
evaluate properly.
. All of the listed recommendations for implantation of a
device presume the absence of inciting causes that may
be eliminated without detriment to the patient (e.g.,
nonessential drug therapy).
. The committee endeavored to maintain consistency of
recommendations in this and other previously published
guidelines. The recommendations on atrioventricular
(AV) block associated with acute myocardial infarction
closely follow those in the “ACC/AHA Guidelines for
the Management of Patients With ST-Elevation Myo-
cardial Infarction” (8). However, because of the rapid
evolution of pacemaker/ICD science, it has not always
been possible to maintain consistency with other pub-
lished guidelines.
The following represents the complete set of recommen-
ations for the implantation of antiarrhythmia devices. Prior
xecutive summaries of ACC/AHA guidelines have in-
luded variable amounts of explanatory text ranging from
one to large amounts. Because the supporting text in the
able 2. Choice of Pacemaker Generator in Selected Indication
Pacemaker Generator Sinus Node Dysfunction
ingle-chamber atrial
pacemaker
No suspected abnormality of atrioventricular
conduction and not at increased risk for
future atrioventricular block
Maintenance of atrioventricular synchrony
during pacing desired
ingle-chamber ventricular
pacemaker
Maintenance of atrioventricular synchrony
during pacing not necessary
Rate response available if desired
ual-chamber pacemaker Atrioventricular synchrony during pacing
desired
Suspected abnormality of atrioventricular
conduction or increased risk for future
atrioventricular block
Rate response available if desired
ingle-lead, atrial-sensing
ventricular pacemaker
Not appropriateull-text document was important to the present writingommittee, we decided to provide only the recommenda-
ions in the Executive Summary and recommend readers
ccess the full-text document for more explanation. Table 2
nd Figures 1 and 2 are provided to help practitioners
hoose which pacing device is appropriate for an individual
atient.
. Recommendations for Permanent Pacing
n Sinus Node Dysfunction
LASS I
. Permanent pacemaker implantation is indicated for sinus node
dysfunction (SND) with documented symptomatic bradycardia,
including frequent sinus pauses that produce symptoms. (Level
of Evidence: C) (9–11)
. Permanent pacemaker implantation is indicated for symptomatic
chronotropic incompetence. (Level of Evidence: C) (9–13)
. Permanent pacemaker implantation is indicated for symptomatic
sinus bradycardia that results from required drug therapy for
medical conditions. (Level of Evidence: C)
LASS IIa
. Permanent pacemaker implantation is reasonable for SND with
heart rate less than 40 bpm when a clear association between
significant symptoms consistent with bradycardia and the actual
presence of bradycardia has not been documented. (Level of
Evidence: C) (9–11,14–16)
. Permanent pacemaker implantation is reasonable for syncope of
unexplained origin when clinically significant abnormalities of
sinus node function are discovered or provoked in electrophysi-
ological studies. (Level of Evidence: C) (17,18)
LASS IIb
. Permanent pacemaker implantation may be considered in mini-
mally symptomatic patients with chronic heart rate less than 40
Pacing
Atrioventricular Block
Neurally Mediated Syncope or
Carotid Sinus Hypersensitivity
ppropriate Not appropriate
ic atrial fibrillation or other atrial
hyarrhythmia or maintenance of
ioventricular synchrony during pacing not
cessary
Chronic atrial fibrillation or
other atrial tachyarrhythmia
Rate response available if
desired
response available if desired
response available if desired
entricular synchrony during pacing desired
pacing desired
response available if desired
Sinus mechanism present
Rate response available if
desired
e to limit the number of pacemaker leads Not appropriates for
Not a
Chron
tac
atr
ne
Rate
Rate
Atriov
Atrial
Rate
Desirbpm while awake. (Level of Evidence: C) (9,11,12,14–16)
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. Permanent pacemaker implantation is not indicated for SND in
asymptomatic patients. (Level of Evidence: C)
. Permanent pacemaker implantation is not indicated for SND in
patients for whom the symptoms suggestive of bradycardia have
been clearly documented to occur in the absence of bradycardia.
(Level of Evidence: C)
. Permanent pacemaker implantation is not indicated for SND with
symptomatic bradycardia due to nonessential drug therapy.
(Level of Evidence: C)
. Recommendations for Acquired
trioventricular Block in Adults
LASS I
. Permanent pacemaker implantation is indicated for third-degree
and advanced second-degree AV block at any anatomic level
associated with bradycardia with symptoms (including heart
failure) or ventricular arrhythmias presumed to be due to AV
block. (Level of Evidence: C) (15,19–21)
. Permanent pacemaker implantation is indicated for third-degree
and advanced second-degree AV block at any anatomic level
associated with arrhythmias and other medical conditions that
require drug therapy that results in symptomatic bradycardia.
(Level of Evidence: C) (15,19–21)
. Permanent pacemaker implantation is indicated for third-degree
and advanced second-degree AV block at any anatomic level in
awake, symptom-free patients in sinus rhythm, with documented
igure 1. Selection of Pacemaker Systems for Patients With S
ecisions are illustrated by diamonds. Shaded boxes indicate type of pacemaker. AVperiods of asystole greater than or equal to 3.0 seconds (22) orany escape rate less than 40 bpm, or with an escape rhythm that
is below the AV node. (Level of Evidence: C) (9,14)
. Permanent pacemaker implantation is indicated for third-degree
and advanced second-degree AV block at any anatomic level in
awake, symptom-free patients with atrial fibrillation and brady-
cardia with 1 or more pauses of at least 5 seconds or longer.
(Level of Evidence: C)
. Permanent pacemaker implantation is indicated for third-degree
and advanced second-degree AV block at any anatomic level
after catheter ablation of the AV junction. (Level of Evidence: C)
(23,24)
. Permanent pacemaker implantation is indicated for third-degree
and advanced second-degree AV block at any anatomic level
associated with postoperative AV block that is not expected to
resolve after cardiac surgery. (Level of Evidence: C) (21,25–27)
. Permanent pacemaker implantation is indicated for third-degree
and advanced second-degree AV block at any anatomic level
associated with neuromuscular diseases with AV block, such as
myotonic muscular dystrophy, Kearns-Sayre syndrome, Erb dys-
trophy (limb-girdle muscular dystrophy), and peroneal muscular
atrophy, with or without symptoms. (Level of Evidence: B) (28–34)
. Permanent pacemaker implantation is indicated for second-
degree AV block with associated symptomatic bradycardia re-
gardless of type or site of block. (Level of Evidence: B) (35)
. Permanent pacemaker implantation is indicated for asymptom-
atic persistent third-degree AV block at any anatomic site with
average awake ventricular rates of 40 bpm or faster if cardio-
megaly or left ventricular (LV) dysfunction is present or if the site
Node Dysfunction
ates atrioventricular.inusof block is below the AV node. (Level of Evidence: B) (20,36)
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third-degree AV block during exercise in the absence of myo-
cardial ischemia. (Level of Evidence: C) (37,38)
LASS IIa
. Permanent pacemaker implantation is reasonable for persistent
third-degree AV block with an escape rate greater than 40 bpm
in asymptomatic adult patients without cardiomegaly. (Level of
Evidence: C) (15,19–21,38,39)
. Permanent pacemaker implantation is reasonable for asymptom-
atic second-degree AV block at intra- or infra-His levels found at
electrophysiological study. (Level of Evidence: B) (20,35,36)
. Permanent pacemaker implantation is reasonable for first- or
second-degree AV block with symptoms similar to those of
pacemaker syndrome or hemodynamic compromise. (Level of
Evidence: B) (40,41)
. Permanent pacemaker implantation is reasonable for asymptom-
atic type II second-degree AV block with a narrow QRS. When type
II second-degree AV block occurs with a wide QRS, including
isolated right bundle-branch block, pacing becomes a Class I
recommendation. (See Section 2.1.3, “Chronic Bifascicular Block,”
in the full-text guidelines.) (Level of Evidence: B) (20,21,40,42)
LASS IIb
. Permanent pacemaker implantation may be considered for neu-
igure 2. Selection of Pacemaker Systems for Patients With A
ecisions are illustrated by diamonds. Shaded boxes indicate type of pacemaker. AVromuscular diseases such as myotonic muscular dystrophy, Erbdystrophy (limb-girdle muscular dystrophy), and peroneal muscu-
lar atrophy with any degree of AV block (including first-degree AV
block), with or without symptoms, because there may be unpre-
dictable progression of AV conduction disease. (Level of Evi-
dence: B) (28–34)
. Permanent pacemaker implantation may be considered for AV
block in the setting of drug use and/or drug toxicity when the
block is expected to recur even after the drug is withdrawn.
(Level of Evidence: B) (43,44)
LASS III
. Permanent pacemaker implantation is not indicated for asymp-
tomatic first-degree AV block. (Level of Evidence: B) (45) (See
Section 2.1.3, “Chronic Bifascicular Block,” in the full-text
guidelines.)
. Permanent pacemaker implantation is not indicated for asymp-
tomatic type I second-degree AV block at the supra-His (AV
node) level or that which is not known to be intra- or infra-Hisian.
(Level of Evidence: C) (35)
. Permanent pacemaker implantation is not indicated for
AV block that is expected to resolve and is unlikely to recur
(46) (e.g., drug toxicity, Lyme disease, or transient in-
creases in vagal tone, or during hypoxia in sleep apnea
syndrome in the absence of symptoms). (Level of Evidence: B)
entricular Block
ates atrioventricular.triov(44,46)
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n Chronic Bifascicular Block
LASS I
. Permanent pacemaker implantation is indicated for advanced
second-degree AV block or intermittent third-degree AV block.
(Level of Evidence: B) (19,39,47–51)
. Permanent pacemaker implantation is indicated for type II
second-degree AV block. (Level of Evidence: B) (52–55)
. Permanent pacemaker implantation is indicated for alternating
bundle-branch block. (Level of Evidence: C) (56)
LASS IIa
. Permanent pacemaker implantation is reasonable for syncope
not demonstrated to be due to AV block when other likely causes
have been excluded, specifically ventricular tachycardia (VT).
(Level of Evidence: B) (55,57–74)
. Permanent pacemaker implantation is reasonable for an inciden-
tal finding at electrophysiological study of a markedly prolonged
HV interval (greater than or equal to 100 milliseconds) in
asymptomatic patients. (Level of Evidence: B) (65)
. Permanent pacemaker implantation is reasonable for an inciden-
tal finding at electrophysiological study of pacing-induced infra-
His block that is not physiological. (Level of Evidence: B) (72)
LASS IIb
. Permanent pacemaker implantation may be considered in the
setting of neuromuscular diseases such as myotonic muscular
dystrophy, Erb dystrophy (limb-girdle muscular dystrophy), and
peroneal muscular atrophy with bifascicular block or any fascic-
ular block, with or without symptoms. (Level of Evidence: C)
(28–34)
LASS III
. Permanent pacemaker implantation is not indicated for fascicu-
lar block without AV block or symptoms. (Level of Evidence: B)
(59,61,64,65)
. Permanent pacemaker implantation is not indicated for fascicu-
lar block with first-degree AV block without symptoms. (Level of
Evidence: B) (59,61,64,65)
. Recommendations for Permanent
acing After the Acute Phase of
yocardial Infarction*
LASS I
. Permanent ventricular pacing is indicated for persistent second-
degree AV block in the His-Purkinje system with alternating
bundle-branch block or third-degree AV block within or below the
His-Purkinje system after ST-segment elevation myocardial in-
farction. (Level of Evidence: B) (54,75–79)
. Permanent ventricular pacing is indicated for transient advanced
second- or third-degree infranodal AV block and associated
bundle-branch block. If the site of block is uncertain, an electro-
physiological study may be necessary. (Level of Evidence: B)
(75,76)These recommendations are consistent with the “ACC/AHA Guidelines for the
anagement of Patients With ST-Elevation Myocardial Infarction” (8).. Permanent ventricular pacing is indicated for persistent and
symptomatic second- or third-degree AV block. (Level of Evi-
dence: C)
LASS IIb
. Permanent ventricular pacing may be considered for persistent
second- or third-degree AV block at the AV node level, even in the
absence of symptoms. (Level of Evidence: B) (14)
LASS III
. Permanent ventricular pacing is not indicated for transient AV
block in the absence of intraventricular conduction defects.
(Level of Evidence: B) (75)
. Permanent ventricular pacing is not indicated for transient AV
block in the presence of isolated left anterior fascicular block.
(Level of Evidence: B) (77)
. Permanent ventricular pacing is not indicated for new bundle-
branch block or fascicular block in the absence of AV block.
(Level of Evidence: B) (48,75)
. Permanent ventricular pacing is not indicated for persistent
asymptomatic first-degree AV block in the presence of bundle-
branch or fascicular block. (Level of Evidence: B) (75)
. Recommendations for Permanent Pacing
n Hypersensitive Carotid Sinus Syndrome
nd Neurocardiogenic Syncope
LASS I
. Permanent pacing is indicated for recurrent syncope caused by
spontaneously occurring carotid sinus stimulation and carotid
sinus pressure that induces ventricular asystole of more than 3
seconds. (Level of Evidence: C) (80,81)
LASS IIa
. Permanent pacing is reasonable for syncope without clear,
provocative events and with a hypersensitive cardioinhibitory
response of 3 seconds or longer. (Level of Evidence: C) (80)
LASS IIb
. Permanent pacing may be considered for significantly symptom-
atic neurocardiogenic syncope associated with bradycardia doc-
umented spontaneously or at the time of tilt-table testing. (Level
of Evidence: B) (82–85)
LASS III
. Permanent pacing is not indicated for a hypersensitive cardioin-
hibitory response to carotid sinus stimulation without symptoms
or with vague symptoms. (Level of Evidence: C)
. Permanent pacing is not indicated for situational vasovagal
syncope in which avoidance behavior is effective and preferred.
(Level of Evidence: C)
. Recommendations for Pacing After
ardiac Transplantation
LASS I
. Permanent pacing is indicated for persistent inappropriate or
symptomatic bradycardia not expected to resolve and for
other Class I indications for permanent pacing. (Level of
Evidence: C)
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. Permanent pacing may be considered when relative bradycardia
is prolonged or recurrent, which limits rehabilitation or discharge
after postoperative recovery from cardiac transplantation. (Level
of Evidence: C)
. Permanent pacing may be considered for syncope after cardiac
transplantation even when bradyarrhythmia has not been docu-
mented. (Level of Evidence: C)
. Recommendations for Permanent
acemakers That Automatically Detect and
ace to Terminate Tachycardias
LASS IIa
. Permanent pacing is reasonable for symptomatic recurrent su-
praventricular tachycardia that is reproducibly terminated by
pacing when catheter ablation and/or drugs fail to control the
arrhythmia or produce intolerable side effects. (Level of Evi-
dence: C) (86–90)
LASS III
. Permanent pacing is not indicated in the presence of an acces-
sory pathway that has the capacity for rapid anterograde con-
duction. (Level of Evidence: C)
. Recommendations for Pacing to
revent Tachycardia
LASS I
. Permanent pacing is indicated for sustained pause-dependent
VT, with or without QT prolongation. (Level of Evidence: C)
(91,92)
LASS IIa
. Permanent pacing is reasonable for high-risk patients with con-
genital long-QT syndrome. (Level of Evidence: C) (91,92)
LASS IIb
. Permanent pacing may be considered for prevention of symptom-
atic, drug-refractory, recurrent atrial fibrillation in patients with
coexisting SND. (Level of Evidence: B) (93–95)
LASS III
. Permanent pacing is not indicated for frequent or complex
ventricular ectopic activity without sustained VT in the absence
of the long-QT syndrome. (Level of Evidence: C) (97)
. Permanent pacing is not indicated for torsade de pointes VT due
to reversible causes. (Level of Evidence: A) (98,99)
0. Recommendation for Pacing to Prevent
trial Fibrillation
LASS III
. Permanent pacing is not indicated for the prevention of atrial
fibrillation in patients without any other indication for pacemaker
implantation. (Level of Evidence: B) (100)1. Recommendations for Cardiac
esynchronization Therapy in Patients With
evere Systolic Heart Failure
LASS I
. For patients who have LV ejection fraction (LVEF) less than or
equal to 35%, a QRS duration greater than or equal to 0.12
seconds, and sinus rhythm, CRT with or without an ICD is
indicated for the treatment of New York Heart Association
(NYHA) functional Class III or ambulatory Class IV heart failure
symptoms with optimal recommended medical therapy. (Level of
Evidence: A) (101,101a–101c)
LASS IIa
. For patients who have LVEF less than or equal to 35%, a QRS
duration greater than or equal to 0.12 seconds, and atrial
fibrillation, CRT with or without an ICD is reasonable for the
treatment of NYHA functional Class III or ambulatory Class IV
heart failure symptoms on optimal recommended medical ther-
apy. (Level of Evidence: B) (101,102)
. For patients with LVEF less than or equal to 35% with NYHA
functional Class III or ambulatory Class IV symptoms who are
receiving optimal recommended medical therapy and who have
frequent dependence on ventricular pacing, CRT is reasonable.
(Level of Evidence: C) (101)
LASS IIb
. For patients with LVEF less than or equal to 35% with NYHA
functional Class I or II symptoms who are receiving optimal
recommended medical therapy undergoing implantation of a
permanent pacemaker and/or ICD with anticipated frequent
ventricular pacing, CRT may be considered. (Level of Evidence:
C) (101)
LASS III
. CRT is not indicated for asymptomatic patients with reduced
LVEF in the absence of other indications for pacing. (Level of
Evidence: B) (101,101a–101c)
. CRT is not indicated for patients whose functional status and life
expectancy are limited predominantly by chronic noncardiac
conditions. (Level of Evidence: C) (101)
2. Recommendations for Pacing in Patients
ith Hypertrophic Cardiomyopathy
LASS I
. Permanent pacing is indicated for SND or AV block in patients
with hypertrophic cardiomyopathy as described previously (see
Section 2.1.1, “Sinus Node Dysfunction,” and Section 2.1.2,
“Acquired Atrioventricular Block in Adults,” in the full-text guide-
lines). (Level of Evidence: C)
LASS IIb
. Permanent pacing may be considered in medically refractory
symptomatic patients with hypertrophic cardiomyopathy and
significant resting or provoked LV outflow tract obstruction.
(Level of Evidence: A) As for Class I indications, when risk
factors for SCD are present, consider a DDD ICD (see Section 3,
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in the full-text guidelines). (103–108)
LASS III
. Permanent pacemaker implantation is not indicated for patients
who are asymptomatic or whose symptoms are medically con-
trolled. (Level of Evidence: C)
. Permanent pacemaker implantation is not indicated for symp-
tomatic patients without evidence of LV outflow tract obstruc-
tion. (Level of Evidence: C)
3. Recommendations for Permanent Pacing
n Children, Adolescents, and Patients With
ongenital Heart Disease
LASS I
. Permanent pacemaker implantation is indicated for advanced
second- or third-degree AV block associated with symptomatic
bradycardia, ventricular dysfunction, or low cardiac output.
(Level of Evidence: C)
. Permanent pacemaker implantation is indicated for SND with
correlation of symptoms during age-inappropriate bradycardia.
The definition of bradycardia varies with the patient’s age and
expected heart rate. (Level of Evidence: B) (9,22,109,110)
. Permanent pacemaker implantation is indicated for postopera-
tive advanced second- or third-degree AV block that is not
expected to resolve or that persists at least 7 days after cardiac
surgery. (Level of Evidence: B) (35,111)
. Permanent pacemaker implantation is indicated for congenital
third-degree AV block with a wide QRS escape rhythm, complex
ventricular ectopy, or ventricular dysfunction. (Level of Evidence:
B) (113–115)
. Permanent pacemaker implantation is indicated for congenital
third-degree AV block in the infant with a ventricular rate less
than 55 bpm or with congenital heart disease and a ventricular
rate less than 70 bpm. (Level of Evidence: C) (116,117)
LASS IIa
. Permanent pacemaker implantation is reasonable for patients
with congenital heart disease and sinus bradycardia for the
prevention of recurrent episodes of intra-atrial re-entrant tachy-
cardia; SND may be intrinsic or secondary to antiarrhythmic
treatment. (Level of Evidence: C) (118–120)
. Permanent pacemaker implantation is reasonable for congenital
third-degree AV block beyond the first year of life with an average
heart rate less than 50 bpm, abrupt pauses in ventricular rate
that are 2 or 3 times the basic cycle length, or associated with
symptoms due to chronotropic incompetence. (Level of Evi-
dence: B) (121,122)
. Permanent pacemaker implantation is reasonable for sinus bra-
dycardia with complex congenital heart disease with a resting
heart rate less than 40 bpm or pauses in ventricular rate longer
than 3 seconds. (Level of Evidence: C)
. Permanent pacemaker implantation is reasonable for patients with
congenital heart disease and impaired hemodynamics due to sinus
bradycardia or loss of AV synchrony. (Level of Evidence: C) (123)
. Permanent pacemaker implantation is reasonable for unex-
plained syncope in the patient with prior congenital heart surgery
complicated by transient complete heart block with residual Dfascicular block after a careful evaluation to exclude other
causes of syncope. (Level of Evidence: B) (115,124–126)
LASS IIb
. Permanent pacemaker implantation may be considered for tran-
sient postoperative third-degree AV block that reverts to sinus
rhythm with residual bifascicular block. (Level of Evidence: C) (127)
. Permanent pacemaker implantation may be considered for con-
genital third-degree AV block in asymptomatic children or ado-
lescents with an acceptable rate, a narrow QRS complex, and
normal ventricular function. (Level of Evidence: B) (113,122)
. Permanent pacemaker implantation may be considered for
asymptomatic sinus bradycardia after biventricular repair of
congenital heart disease with a resting heart rate less than 40
bpm or pauses in ventricular rate longer than 3 seconds. (Level
of Evidence: C)
LASS III
. Permanent pacemaker implantation is not indicated for transient
postoperative AV block with return of normal AV conduction in
the otherwise asymptomatic patient. (Level of Evidence: B)
(127,127a)
. Permanent pacemaker implantation is not indicated for asymp-
tomatic bifascicular block with or without first-degree AV block
after surgery for congenital heart disease in the absence of prior
transient complete AV block. (Level of Evidence: C)
. Permanent pacemaker implantation is not indicated for asymp-
tomatic type I second-degree AV block. (Level of Evidence: C)
. Permanent pacemaker implantation is not indicated for asymp-
tomatic sinus bradycardia with the longest relative risk interval
less than 3 seconds and a minimum heart rate more than 40
bpm. (Level of Evidence: C)
4. Recommendations for Implantable
ardioverter-Defibrillators
econdary prevention refers to the prevention of SCD in
hose patients who have survived a prior cardiac arrest or
ustained VT. Primary prevention refers to the prevention
f SCD in individuals without a history of cardiac arrest or
ustained VT. Patients with cardiac conditions associated
ith a high risk of sudden death who have unexplained
yncope that is likely to be due to ventricular arrhythmias are
onsidered to have a secondary indication.
Recommendations for consideration of ICD therapy,
articularly those for primary prevention, apply only to
atients who are receiving optimal medical therapy and have
reasonable expectation of survival with good functional
tatus for more than 1 year. It is difficult to estimate survival
ith heart failure in the general population, for whom
omorbidities and age differ from those in trial populations
rom which the predictive models have been derived. Pa-
ients with repeated heart failure hospitalizations, particu-
arly in the presence of reduced renal function, are at high
isk for early death due to heart failure (128–130). Please
ee Section 3, “Indications for Implantable Cardioverter-
efibrillator Therapy,” in the full-text guidelines for dis-
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nclusion criteria.
We acknowledge that the “ACC/AHA/ESC 2006
uidelines for Management of Patients With Ventricular
rrhythmias and the Prevention of Sudden Cardiac Death”
4) used an LVEF of less than 40% as a critical point to
ustify ICD implantation for primary prevention of SCD.
he LVEF used in clinical trials assessing the ICD for
rimary prevention of SCD ranged from less than 40% in
USTT (Multicenter Unsustained Ventricular Tachycar-
ia Trial) to less than 30% in MADIT II (Multicenter
utomatic Defibrillator Implantation Trial II) (131,132).
wo trials, MADIT I (Multicenter Automatic Defibrillator
mplantation Trial I) (6) and SCD-HeFT (Sudden Cardiac
eath in Heart Failure Trial) (7) used LVEFs of less than
5% as entry criteria. The present writing committee
eached the consensus that it would be best to offer ICDs to
atients with clinical profiles as similar to those included in
he trials as possible. Having given careful consideration to
he issues related to LVEF for these updated ICD guide-
ines, we have written these indications for ICDs on the
asis of the specific inclusion criteria for LVEF in the trials.
ecause of this, there may be some variation from previously
ublished guidelines (4).
We also acknowledge that the determination of LVEF
acks a “gold standard” and that there may be variation
mong the commonly used clinical techniques of LVEF
etermination. All clinical methods of LVEF determination
ack precision, and the accuracy of techniques varies among
aboratories and institutions. On the basis of these consid-
rations, the present writing committee recommends that
linicians use the LVEF determination that they believe
s the most clinically accurate and appropriate in their
nstitution.
LASS I
. ICD therapy is indicated in patients who are survivors of cardiac
arrest due to ventricular fibrillation or hemodynamically unstable
sustained VT after evaluation to define the cause of the event
and to exclude any completely reversible causes. (Level of
Evidence: A) (4,133–138)
. ICD therapy is indicated in patients with structural heart disease
and spontaneous sustained VT, whether hemodynamically stable
or unstable. (Level of Evidence: B) (4,133–138)
. ICD therapy is indicated in patients with syncope of undeter-
mined origin with clinically relevant, hemodynamically signifi-
cant sustained VT or ventricular fibrillation induced at electro-
physiological study. (Level of Evidence: B) (4,136)
. ICD therapy is indicated in patients with LVEF less than 35% due
to prior myocardial infarction who are at least 40 days post--
myocardial infarction and are in NYHA functional Class II or III.
(Level of Evidence: A) (4,139)
. ICD therapy is indicated in patients with nonischemic dilated
cardiomyopathy who have an LVEF less than or equal to 35% and
who are in NYHA functional Class II or III. (Level of Evidence: B)
(4,139–141)
. ICD therapy is indicated in patients with LV dysfunction due to
prior myocardial infarction who are at least 40 days post--
†
dmyocardial infarction, have an LVEF less than 30%, and are in
NYHA functional Class I. (Level of Evidence: A) (4,132)
. ICD therapy is indicated in patients with nonsustained VT due to
prior myocardial infarction, LVEF less than 40%, and inducible
ventricular fibrillation or sustained VT at electrophysiological
study. (Level of Evidence: B) (4,131,142)
LASS IIa
. ICD implantation is reasonable for patients with unexplained
syncope, significant LV dysfunction, and nonischemic dilated
cardiomyopathy. (Level of Evidence: C)
. ICD implantation is reasonable for patients with sustained VT
and normal or near-normal ventricular function. (Level of Evi-
dence: C)
. ICD implantation is reasonable for patients with hypertrophic
cardiomyopathy who have 1 or more major† risk factor for SCD.
(Level of Evidence: C)
. ICD implantation is reasonable for the prevention of SCD in
patients with arrhythmogenic right ventricular dysplasia/cardio-
myopathy who have 1 or more risk factor for SCD. (Level of
Evidence: C)
. ICD implantation is reasonable to reduce SCD in patients with
long-QT syndrome who are experiencing syncope and/or VT while
receiving beta blockers. (Level of Evidence: B) (143–148)
. ICD implantation is reasonable for nonhospitalized patients
awaiting transplantation. (Level of Evidence: C)
. ICD implantation is reasonable for patients with Brugada syn-
drome who have had syncope. (Level of Evidence: C)
. ICD implantation is reasonable for patients with Brugada syn-
drome who have documented VT that has not resulted in cardiac
arrest. (Level of Evidence: C)
. ICD implantation is reasonable for patients with catecholamin-
ergic polymorphic VT who have syncope and/or documented sus-
tained VT while receiving beta blockers. (Level of Evidence: C)
0. ICD implantation is reasonable for patients with cardiac sar-
coidosis, giant cell myocarditis, or Chagas disease. (Level of
Evidence: C)
LASS IIb
. ICD therapy may be considered in patients with nonischemic
heart disease who have an LVEF of less than or equal to 35% and
who are in NYHA functional Class I. (Level of Evidence: C)
. ICD therapy may be considered for patients with long-QT syndrome
and risk factors for SCD. (Level of Evidence: B) (4,143–148)
. ICD therapy may be considered in patients with syncope and
advanced structural heart disease in whom thorough invasive
and noninvasive investigations have failed to define a cause.
(Level of Evidence: C)
. ICD therapy may be considered in patients with a familial
cardiomyopathy associated with sudden death. (Level of Evi-
dence: C)
. ICD therapy may be considered in patients with LV noncompac-
tion. (Level of Evidence: C)
LASS III
. ICD therapy is not indicated for patients who do not have a
reasonable expectation of survival with an acceptable functional
status for at least 1 year, even if they meet ICD implantationSee Section 3.2.4, “Hypertrophic Cardiomyopathy,” in the full-text guidelines for
efinition of major risk factors.
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above. (Level of Evidence: C)
. ICD therapy is not indicated for patients with incessant VT or
ventricular fibrillation. (Level of Evidence: C)
. ICD therapy is not indicated in patients with significant psychi-
atric illnesses that may be aggravated by device implantation or
that may preclude systematic follow-up. (Level of Evidence: C)
. ICD therapy is not indicated for NYHA Class IV patients with drug-
refractory congestive heart failure who are not candidates for cardiac
transplantation or implantation of a CRT device that incorporates both
pacing and defibrillation capabilities. (Level of Evidence: C)
. ICD therapy is not indicated for syncope of undetermined cause
in a patient without inducible ventricular tachyarrhythmias and
without structural heart disease. (Level of Evidence: C)
. ICD therapy is not indicated when ventricular fibrillation or VT is
amenable to surgical or catheter ablation (e.g., atrial arrhythmias
associated with Wolff-Parkinson-White syndrome, right ventricular
or LV outflow tract VT, idiopathic VT, or fascicular VT in the absence
of structural heart disease). (Level of Evidence: C)
. ICD therapy is not indicated for patients with ventricular tachy-
arrhythmias due to a completely reversible disorder in the
absence of structural heart disease (e.g., electrolyte imbalance,
drugs, or trauma). (Level of Evidence: B) (4)
5. Recommendations for Implantable
ardioverter-Defibrillators in Pediatric
atients and Patients With Congenital
eart Disease
LASS I
. ICD implantation is indicated in the survivor of cardiac arrest
after evaluation to define the cause of the event and to exclude
any reversible causes. (Level of Evidence: B) (149–152)
. ICD implantation is indicated for patients with symptomatic
sustained VT in association with congenital heart disease who
have undergone hemodynamic and electrophysiological evalua-
tion. Catheter ablation or surgical repair may offer possible
alternatives in carefully selected patients. (Level of Evidence: C)
(153)
LASS IIa
. ICD implantation is reasonable for patients with congenital heart
disease with recurrent syncope of undetermined origin in the
presence of either ventricular dysfunction or inducible ventricular
arrhythmias at electrophysiological study. (Level of Evidence: B)
(6,154)
LASS Ib
. ICD implantation may be considered for patients with recurrent
syncope associated with complex congenital heart disease and
advanced systemic ventricular dysfunction when thorough inva-
sive and noninvasive investigations have failed to define a cause.
(Level of Evidence: C) (155,156)
LASS III
. All Class III recommendations found in Section 3 of the full-text
guidelines, “Indications for Implantable Cardioverter-Defibrillator
Therapy,” apply to pediatric patients or patients with congenital
heart disease, and ICD implantation is not indicated in these
patient populations. (Level of Evidence: C)taff
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